Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of clarithromycin on airway obstruction and inflammatory markers ininduced sputum in cystic fibrosis: A pilot study
Autore:
Ordonez, CL; Stulbarg, M; Grundland, H; Liu, JT; Boushey, HA;
Indirizzi:
Childrens Hosp, Dept Med, Boston, MA 02115 USA Childrens Hosp Boston MA USA 02115 s Hosp, Dept Med, Boston, MA 02115 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USAUniv Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA Univ Calif San Francisco, Dept Med Allergy & Immunol, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA
Titolo Testata:
PEDIATRIC PULMONOLOGY
fascicolo: 1, volume: 32, anno: 2001,
pagine: 29 - 37
SICI:
8755-6863(200107)32:1<29:EOCOAO>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
BRONCHIAL EPITHELIAL-CELLS; BRONCHOALVEOLAR LAVAGE FLUID; NECROSIS-FACTOR-ALPHA; PSEUDOMONAS-AERUGINOSA; POTENTIAL MECHANISM; HEALTHY-SUBJECTS; ERYTHROMYCIN; ASTHMA; ROXITHROMYCIN; CHILDREN;
Keywords:
cystic fibrosis; inflammation; sputum induction; inflammatory marker; macrolides;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Ordonez, CL Childrens Hosp, Div Resp Dis, 300 Longwood Ave, Boston, MA 02115 USA Childrens Hosp 300 Longwood Ave Boston MA USA 02115 02115 USA
Citazione:
C.L. Ordonez et al., "Effect of clarithromycin on airway obstruction and inflammatory markers ininduced sputum in cystic fibrosis: A pilot study", PEDIAT PULM, 32(1), 2001, pp. 29-37

Abstract

To determine whether macrolide antibiotics improve pulmonary function and decrease airway inflammation in cystic fibrosis (CF), we treated 10 patients (4 females; aged 19-26 years, all colonized with P. aeruginosa, none withatypical Mycobacteria) with 3 weeks of placebo, followed by 6 weeks of clarithromycin (500 mg BID) in a single-blind prospective study. We also determined the safety of sputum induction and the reproducibility of assessing inflammatory markers in induced sputum. Subjects performed spirometry and underwent sputum induction (12-min inhalation of 3% saline) at 3-week intervals. We found that sputum induction was well-tolerated. We also found that the reproducibility was high for neutrophil (PMN) number (R = 0.87, P = 0.009),interleukin (IL)-8 (R = 0.73, P < 0.05), free neutrophil elastase (NE) (R = 0.82, P < 0.05), and myeloperoxidase (MPO) levels (R = 0.86, P < 0.05), but was less so for tumor necrosis factor (TNF)-alpha (R = -0.15, P = 0.7). We found no significant difference in pulmonary function after 6 weeks of treatment with clarithromycin (FEV, (% predicted) (mean +/- SEM), 2.2 +/- 0.9 (60 +/- 24%) vs. 2.3 +/- 1 (61 +/- 29%)), and no significant differences in any of the inflammatory indices measured. The median land range) values before and after treatment for indices of airway inflammation in the induced sputum samples were: for PMNs, 8 (1-326) and 21 (0.2 -175) x 10(6) cells/mL sputum; for IL-8, 156 (24-656) and 202 (16-680) ng/mL; for free NE, 260 (31-1,264) and 237 (49-1,048) mug/mL; for TNF-alpha(, 20 (7-128) and 35 (17-87) pg/mL; and for MPO, 169 (13-960) and 195 (14-816) mug/mL. We conclude that clarithromycin is not uniformly effective in improving airway obstruction or in decreasing airway inflammation in patients with CF. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 11:51:03